Molecular mechanism underlying the impact of vitamin D on disease activity of MS

Annals of Clinical and Translational Neurology

Volumn 1, Issue 8, 2014, Pages 605-617

  Munger, Kassandra L ^a   Köchert, Karl ^b   Simon, Kelly C ^a   Kappos, Ludwig ^c   Polman, Chris H ^d   Freedman, Mark S ^e   Hartung, Hans P ^f   Miller, David H ^g   Montalbán, Xavier ^h   Edan, Gilles ⁱ   Barkhof, Frederik ^d   Pleimes, Dirk ^b   Sandbrink, Rupert ^b,f   Ascherio, Alberto ^a   Pohl, Christoph ^b,j  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL BONN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; SPHINGOSINE 1 PHOSPHATE; VITAMIN D;

ADULT; ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 84924811795     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.91     Document Type: Article

References (54)

1. Ascherio A, Munger KL, Lunemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012;8:602–612.
2. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67:618–624.
3. Runia TF, Hop WC, de Rijke YB, et al. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79:261–266.
4. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193–203.
5. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234–240.
6. Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:565–571.
7. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010;74:1852–1859.
8. Holmoy T, Lossius A, Gundersen TE, et al. Intrathecal levels of vitamin D and IgG in multiple sclerosis. Acta Neurol Scand 2012;125:e28–e31.
9. Pozuelo-Moyano B, Benito-Leon J, Mitchell AJ, et al. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology 2013;40:147–153.
10. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242–1249.
11. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389–397.
12. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987–997.
13. Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014;71:306–314.
14. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am 2010;39:365–379.
15. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158–164.
16. Nagtegaal GJ, Pohl C, Wattjes MP, et al. Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Mult Scler 2014;20:234–242.
17. Irizarry RA, Bolstad BM, Collin F, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
18. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185–193.
19. Dai M, Wang P, Boyd AD, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005;33:e175.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;51:289–300.
21. Bonferroni C. Il calcolo delle assicurazioni su gruppi di teste. Studi in Onore del Professore Salvator Ortu Carboni, Rome, Italy 1935: 13–60.
22. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545–15550.
23. Heikkinen S, Vaisanen S, Pehkonen P, et al. Nuclear hormone 1alpha,25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy. Nucleic Acids Res 2011;39:9181–9193.
24. Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010;20:1352–1360.
25. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:3.
26. Bailey TL, Boden M, Buske FA, et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res 2009;37:W202–W208.
27. Bryne JC, Valen E, Tang MH, et al. JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res 2008;36:D102–D106.
28. Levy DE, Kessler DS, Pine R, et al. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev 1988;2:383–393.
29. Aktas O, Kury P, Kieseier B, et al. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010;6:373–382.
30. Mehling M, Johnson TA, Antel J, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011;76:S20–S27.
31. Handel AE, Sandve GK, Disanto G, et al. Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease. BMC Med 2013;11:163.
32. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006;147:5542–5548.
33. Norman AW. A vitamin D nutritional cornucopia: new insights concerning the serum 25-hydroxyvitamin D status of the US population. Am J Clin Nutr 2008;88:1455–1456.
34. Stambolsky P, Tabach Y, Fontemaggi G, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010;17:273–285.
35. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–281.
36. Broad Institute. Gene set enrichment analysis: GSEA user guide. Available at http://www.broadinstitute.org/gsea/GSEAUserGuide.pdf. Accessed 1 June 2014.
37. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013;41:D808–D815.
38. Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol 2012;90:252–268.
39. Auer DP, Schumann EM, Kumpfel T, et al. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;47:276–277.
40. Killestein J, Rep MH, Meilof JF, et al. Seasonal variation in immune measurements and MRI markers of disease activity in MS. Neurology 2002;58:1077–1080.
41. Rovaris M, Comi G, Sormani MP, et al. Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. Ann Neurol 2001;49:415–416.
42. Smolders J, Thewissen M, Theunissen R, et al. Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis. J Neuroimmunol 2011;235:91–97.
43. Smolders J, Schuurman KG, van Strien ME, et al. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J Neuropathol Exp Neurol 2013;72:91–105.
44. Comabella M, Lunemann JD, Rio J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009;132:3353–3365.
45. Gandhi KS, McKay FC, Cox M, et al. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet 2010;19:2134–2143.
46. Nickles D, Chen HP, Li MM, et al. Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Hum Mol Genet 2013;22:4194–4205.
47. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006;7:522–531.
48. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576–1582.
49. Croze E, Yamaguchi KD, Knappertz V, et al. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J 2013;13:443–451.
50. van Baarsen LG, Vosslamber S, Tijssen M, et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008;3:e1927.
51. Satoh J, Tabunoki H. Molecular network of chromatin immunoprecipitation followed by deep sequencing-based vitamin D receptor target genes. Mult Scler 2013;19:1035–1045.
52. Costa EM, Hirst MA, Feldman D. Regulation of 1,25-dihydroxyvitamin D3 receptors by vitamin D analogs in cultured mammalian cells. Endocrinology 1985;117:2203–2210.
53. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004;29:664–673.
54. Zierold C, Darwish HM, DeLuca HF. Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter. J Biol Chem 1995;270:1675–1678.